ClinicalTrials.gg
CompletedNCT04165239Updated Aug 31, 2022

The KHENERGYZE Study

A Phase 2 interventional study of KH176 and KH176 in Mitochondrial Diseases, Mitochondrial Myopathies and Mitochondrial Encephalomyopathies, sponsored by Khondrion BV. Completed at 4 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-31.

Primary conditionMELAS SyndromeRegistry: Mitochondrial DiseasesReclassifiedWhy we changed it
Registry
Mitochondrial Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
MELAS Syndrome
Why
  1. The study's listed conditions name MELAS Syndrome, a narrower term within Mitochondrial Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Khondrion BV · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Mitochondrial diseases, estimated prevalence 1 in 4,300 adults, is caused by pathogenic mutations in genes finally encoding for mitochondrial proteins of the various enzyme complexes of the OXPHOS. Among these mutations, the 3243A>G nucleotide change in the mitochondrially encoded transfer RNALeu(UUR) leucine 1 gene (MT TL 1) is the most prevalent one. The OXPHOS dysfunction resulting from such mutations leads to increased production of reactive oxygen species (ROS), ultimately leading to irreversible oxidative damage of macromolecules, or to more selective and reversible redox modulation of cell signaling that may impact (adult) neurogenesis.

Despite advances in the understanding of mitochondrial disorders, treatment options are extremely limited and, to date, largely supportive. Therefore, there is an urgent need for novel treatments. KH176, a new active pharmaceutical ingredient (API), is an orally bio-available small molecule under development for the treatment of these disorders (see Section 1.4). The current study will further evaluate the effect of KH176 in various cognitive domains and evaluate the effect of different doses of KH176 (See Section 1.5).

In view of the growing recognition of the importance of mitochondrial function in maintaining cognitive processes in the brain, as well as the understanding of the safety profile and pharmacokinetics of KH176 following the two clinical studies described above, a more detailed study is indicated of the effects of KH176 in various cognitive domains, using the confirmed safe and well-tolerated KH176 dose of 100 mg bid, as well as a lower dose of 50 mg bid. The primary objective is an evaluation of KH176 in the attention domain of cognitive functioning, as assessed by the visual identification test score of the Cogstate computerised cognitive testing battery.

Read the detailed description

For this study, a 3 x 3 crossover design will be applied, i.e., with 3 treatments, 3 sequences and 3 periods, employing a Latin square assignment. Using this design, each subject will function as his/her own control. This will reduce variability and thus increase the chances of observing true effects between treatment periods (effects of treatment compared to placebo). In each treatment period, assessments will be performed at baseline prior to dosing and post dosing, enabling a change from baseline analysis and enabling the possibility to compare baseline conditions for each treatment period. The treatment period in each treatment is 28 days (4 weeks), which is supported by the pre-clinical toxicology program. In mouse studies, a 4-week period was sufficient to observe clinically relevant effects.

02

Conditions studied

  • Mitochondrial Diseases
  • Mitochondrial Myopathies
  • Mitochondrial Encephalomyopathies
  • MELAS Syndrome
  • MIDD

Browse trials for

Keywords

  • Mitochondrial
  • Oxidative Phosphorylation (OXPHOS)
  • MELAS
  • MIDD
  • KH176
03

In context

MELAS Syndrome Reclassified

37 studies on the registry are indexed under MELAS Syndrome; 8 are open to participants now.

This study's enrollment of 27 is above the median of 24 across 29 interventional studies indexed under MELAS Syndrome.

Browse MELAS Syndrome studies →

Lead sponsor

Khondrion BV is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Compared within MELAS Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Mitochondrial Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  1. Males and females aged 18 years or older at screening.
  2. Ability and willingness to provide written prior to screening evaluations.
  3. Confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G mutation.
  4. Positive NMDAS score >10 at Screening.
  5. Three or more clinical features, with no other causative unifying diagnosis, found to commonly occur in subjects with a m.3243A>G mutation:

    • Deafness
    • Developmental delay
    • Diabetes Mellitus
    • Epilepsy
    • Gastrointestinal complaints
    • Progressive External Ophtalmoplegia (PEO) and retinopathy
    • Ataxia
    • Exercise intolerance
    • Fatigue
    • Migraine (with or without aura), specified by at least five attacks fulfilling diagnostic criteria B-D:

B. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)

C. Headache has at least two of the following four characteristics:

  1. unilateral location
  2. pulsating quality
  3. moderate or severe pain intensity
  4. aggravation or causing avoidance of routine physical activity (e.g. walking or climbing stairs)

D. During headache at least one of the following:

  1. nausea and/or vomiting 2. photophobia and phonophobia 6. Attentional dysfunction score (Cogstate Identification test) ≥ 0.5 standard deviations poorer than healthy controls at Screening.
  1. Disease appropriate physical and mental health as established at Screening by medical history, physical examination, and vital signs recording, and results of clinical chemistry and haematology testing as judged by the investigator.
  1. Objectified (LVEF) ≥45% (echocardiography, or otherwise).
  1. Left Ventricular (LV) wall thickness ≤15 mm. 10. Left atrium dilatation ≤ 40 mL/m2. Note: No need to test LV parameters (criteria #8, #9, #10) if favourable echocardiography (or otherwise) results dated less than 6 months prior to Screening are available.
  1. Women of must be willing to use highly effective methods during the entire study, i.e., combined (estrogen and progestogen containing) oral, intravaginal or transdermal hormonal contraception associated with inhibition of ovulation;, oral, injectable or implantable progestogen-only hormonal contraception associated with inhibition of ovulation; use of an intrauterine device; an intrauterine hormone releasing system, bilateral tubal occlusion and vasectomy of the partner.

Any hormonal contraception method must be supplemented with a barrier method (preferably male condom).

Vasectomised partner is considered a highly effective birth control method provided that partner is the sole sexual partner of the subject and that the vasectomised partner has received medical assessment of the surgical success. Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. Reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.

Note 1: Natural family planning methods, female condom, cervical cap or diaphragm are not considered adequate contraceptive methods in the context of this study.

Note 2: To be considered not of childbearing potential, potential female subjects must be for at least two years, or have been surgically sterilised (bilateral tubal ligation, hysterectomy or bilateral oophorectomy) for at least 6 months prior to Screening.

Note 3: KH176 has been shown non-genotoxic judged from the Ames test, Chromosomal Aberration test and in vivo Micronucleus test. Moreover, appreciable systemic exposure from the exposure to (\~2.5 mL) semen is extremely unlikely. However, until reproductive toxicology studies have confirmed that KH176 does not adversely affect normal reproduction in adult males and females, as well as causing developmental toxicity in the offspring, the following contraceptive precautions must be adhered to:

  • male subjects with female partners of childbearing potential must be willing to use condoms during the entire study.
  • female partners of childbearing potential of male subjects must be willing to use adequate contraceptive methods during the entire study, i.e., a hormonal contraceptive method (pill, vaginal ring, patch, implant, injectable, hormone-medicated intrauterine device) or an intrauterine device.

    1. Able to comply with the study requirements, including swallowing study medication.

Exclusion Criteria

  1. Surgery of gastro-intestinal tract that might interfere with absorption.
  2. Treatment with an product within 3 months or 5 times the half-life of the investigational product (whichever is longer) prior to the first dose of the study medication.
  3. Documented history of ventricular tachycardia (HR>110 beats/min).
  4. History of acute heart failure, (family) history of unexplained syncope or congenital long and short syndrome or sudden death.
  5. abnormal laboratory, vital signs or physical or mental health;

    1. (ASAT) or alanine aminotransferase (ALAT) > 3 x (ULN), or > 3 x ULN at screening. If a patient has ASAT or ALAT > 3 x ULN but \< 3.5 x ULN, re-assessment is allowed at the investigator's discretion.
    2. Estimated ≤ 60 mL/min according to the CKD-EPI formula at screening.
    3. Systolic Blood pressure > 150 mmHg at screening or baseline.
    4. All other clinically relevant parameters at screening or baseline as judged by the Investigator.
  6. Clinically relevant abnormal ECG or cardiac functioning, defined as ST-segment elevation > 1 mm in I, II, III, aVL ,aVF ,V3 ,V4 ,V5 ,V6; > 2 mm in V1, V2; QTc > 450 ms for male subjects; QTc: > 470ms for female subjects (local, machine read), T-top inversion in >1 consecutive lead.
  7. Serum Hyper-potassium (> 5.0 mEq/L).
  8. Serum Hypo-potassium (\< 3.5 mEq/L).
  9. History of ischemic heart disease.
  10. Symptomatic heart failure.
  11. Clinically relevant aorta and/or mitralis valvular defect as judged by the investigator.
  12. Pregnancy or breast feeding (females).
  13. Poor nutritional state as judged by the investigator.
  14. History of or idiosyncrasy to any of the components of the investigational drug.
  15. Medical history of drug abuse (illegal drugs such as cannabinoids, amphetamines, cocaine, opiates or problematic use of prescription drugs such as benzodiazepines, opiates).
  16. The use of any of the following medication and/or supplements within 4 weeks or 5 times the half-life (whichever is longer) prior to the first dosing of the study medication:

    1. (multi)vitamins, co-enzyme Q10, Vitamin E, riboflavin, and anti-oxidant supplements (including, but not limited to idebenone/EPI-743, mitoQ); unless stable for at least one month before first dosing and remaining stable throughout the study.
    2. any medication negatively influencing mitochondrial functioning (including but not limited to valproic acid, glitazones, statins, anti-virals, amiodarone, and non-steroidal anti-inflammatory drugs (NSAIDs)), unless stable for at least one month before first dosing and remaining stable throughout the study.

      Note: thus, mitoQ and any medication negatively influencing mitochondrial functioning are allowed as long as the dose has been stable for at least one month prior to first dosing and remains stable throughout the study.

    3. any strong Cytochrome P450 (CYP)3A4 inhibitors (all 'conazoles-anti-fungals', antivirals, grapefruit).
    4. strong inducers (including HIV antivirals, carbamazepine, phenobarbital, phenytoin, rifampicin, St. John's wort, pioglitazone, troglitazone).
    5. any medication known to affect cardiac repolarisation, unless the QTc interval at screening is normal during stable treatment (all anti-psychotics, several anti-depressants, e.g. nor/amitriptyline, fluoxetine, anti-emetics: domperidone (motilium®) granisetron, ondansetron). For a complete list see https://crediblemeds.org.
    6. any medication metabolised by CYP with a narrow therapeutical width. For reference (Germany and United Kingdom): drug interaction table of Indiana University (http://medicine.iupui.edu/clinpharm/ddis/clinical-table/). For reference (The Netherlands): KNMP Kennisbank (https://www.knmp.nl/producten/knmp-kennisbank/inloggen-knmp-kennisbank. For reference (all other countries): drug interaction table of Indiana University (http://medicine.iupui.edu/clinpharm/ddis/clinical-table/).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Treatment A

    Oral administration of 50 mg KH176 twice daily

    Drug: KH176

  • Experimental
    Treatment B

    Oral administration of 100 mg KH176 twice daily

    Drug: KH176

  • Placebo comparator
    Treatment C

    Oral administration of matching placebo twice daily

    Drug: Placebo

Interventions

  • DrugTroloxStudies of TroloxTrolox pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral administration of 50 mg KH176 twice daily

    Also known as: Sonlicromanol

  • DrugTroloxStudies of TroloxTrolox pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral administration of 100 mg KH176 twice daily

    Also known as: Sonlicromanol

  • DrugPlacebo

    Oral administration of matching placebo twice daily

06

What researchers measure

Primary outcomes

  1. Cognitive functioning: Attention

    The attention domain score of cognitive functioning, as assessed by the visual Identification Test of the Cogstate computerised cognitive testing battery

    Time frame: One month

Secondary outcomes

  1. Executive functioning

    The executive functioning domain score of cognitive functioning, as assessed by the Groton Maze Learning Test of the Cogstate computerised cognitive testing battery

    Time frame: One month

  2. Psychomotor function

    The psychomotor functioning domain score of cognitive functioning, as assessed by the Detection Test of the Cogstate computerised cognitive testing battery

    Time frame: One month

  3. Working Memeory

    The working memory domain score of cognitive functioning, as assessed by the One Back Test of the Cogstate computerised cognitive testing battery

    Time frame: One month

  4. Visual learning

    The visual learning domain score of cognitive functioning, as assessed by the One Card Learning Test of the Cogstate computerised cognitive testing battery

    Time frame: One month

  5. Verbal learning

    The verbal learning functioning domain score of cognitive functioning, as assessed by the International Shopping List Test of the Cogstate computerised cognitive testing battery

    Time frame: One month

  6. Test of Attentional Performance (TAP)

    Standardised test to evaluate alertness and mental flexibility

    Time frame: One month

  7. Beck Depression Inventory

    21-question multiple-choice self-report inventory, for measuring the severity of depression

    Time frame: One month

  8. Hamilton Anxiety and Depression Score (HADS)

    Subject-reported outcome measure and comprises 14 items equally divided over the two subscales anxiety (HADS-A) and depression (HADS-D)

    Time frame: One month

  9. Newcastle Mitochondrial Disease Scale for Adults (NMDAS)

    Semi-quantitative clinical rating scale designed for mitochondrial disease. The rating scale explores several domains: current function, system specific involvement, current clinical assessment and quality of life

    Time frame: One month

  10. Number of headache days

    Self report diary

    Time frame: One month

  11. Pure Tone Audiometry (PTA)

    Standardized test measure individual hearing threshold levels

    Time frame: One month

  12. University of Penn Smell Identification Test (UPSIT)

    Test to measure the individual's ability to detect odors at a suprathreshold level.

    Time frame: One month

  13. Cognitive Failure Questionnaire (CFQ)

    Questionnaire to evaluate subjective cognitive functioning.

    Time frame: One month

  14. Neuro-QoL Fatigue Short Form (quality in life in neurological disorders)

    8-item self assessment questionnaire evaluating the perception of fatigue and its impact in daily life activities

    Time frame: One month

07

Study locations

4 sites
  • Rigshospitalet, University of Copenhagen
    Kopenhagen, DK2100, Denmark
  • Friedrich-Baur Institut
    München, Bayern 80336, Germany
  • Radboud University Medical Center
    Nijmegen, Netherlands
  • Institute for Ageing and Health Newcastle University
    Newcastle upon Tyne, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in May 2022, 30 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2019
First posted
Nov 15, 2019
StartActual
Oct 30, 2019
Primary completionActual
May 24, 2022
CompletionActual
May 24, 2022
Last update
Aug 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04165239
Lead sponsor
Khondrion BV
Collaborators
Julius Clinical
Responsible party
Sponsor
First posted
Nov 15, 2019
Start date
Oct 30, 2019
Primary completion
May 24, 2022
Completion
May 24, 2022
Last update
Aug 31, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trolox

Start the discussion